CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2019--
Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update
at the 37th Annual J.P. Morgan Healthcare Conference onTuesday, January 8, 2018 at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern
Time at the Westin St. Francis Hotel in San Francisco. The presentation
will be followed by a question and answer session that will begin at
10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.
A live webcast of Ironwood’s presentation and the question and answer
session will be accessible through the Investors section of the
company’s website at www.ironwoodpharma.com.
To access the webcast, please log on to the Ironwood website
approximately 15 minutes prior to the start time to ensure adequate time
for any software downloads that may be required. A replay of the webcast
will be available on Ironwood’s website for 14 days following the
About Ironwood Pharmaceuticals
(Nasdaq: IRWD) is a commercial biotechnology company focused on creating
medicines that make a difference for patients, building value for our
fellow shareholders, and empowering our passionate team. We discovered,
developed and are commercializing linaclotide, the U.S. branded
prescription market leader for adults with irritable bowel syndrome with
constipation (IBS-C) or chronic idiopathic constipation (CIC). Our
pipeline priorities for linaclotide include a Phase IIIb trial
evaluating its efficacy and safety on multiple abdominal symptoms,
including abdominal bloating, pain, and discomfort in adult patients
with IBS-C, as well as research into a formulation of linaclotide
designed to relieve pain across all IBS subtypes.
We are also advancing a pipeline of innovative product candidates in
areas of significant unmet need, including persistent gastroesophageal
reflux disease, diabetic nephropathy, heart failure with preserved
ejection fraction and sickle cell disease. Ironwood was founded in 1998
and is headquartered in Cambridge, Mass. For more information, please
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005605/en/
Source: Ironwood Pharmaceuticals, Inc.
Investor and Media Relations
Meredith Kaya, 617-374-5082
President, Investor Relations and Corporate Communications